On Thursday, Japan’s drugmaker Takeda Pharmaceutical Company Limited (NYSE:TAK) announced a restructuring after the company reported a fiscal year 2023 net profit of 144 billion yen (around $954 million), down 54.6% Y/Y. Core net profit fell 12.6% (down 15% at constant currency) to 756.8 billion yen. Takeda said it will incur restructuring costs of about 140 billion yen in fiscal year 2024 as part of a plan to optimize its workforce, cut costs, and strengthen technology.  Revenue was 4.26 trillion (around $28.19 billion), up 5.9% (up 1.5% at constant currency). The increase is primarily attributable to favorable foreign exchange rates and growth from the business momentum of PlasmaDerived Therapies (PDT) Immunology, Gastroenterology (GI), Rare Diseases, and Oncology, offset by ...